Funding for this research was provided by:
National Cancer Institute (P50-CA58223)
Ministerio de Economía, Industria y Competitividad, Gobierno de España (PI 15/00117, PI 12/02684)
Text and Data Mining valid from 2019-06-03
Received: 28 September 2018
Accepted: 27 May 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: The study was approved by the Spanish Health Authority (MMJ-CAR-2014-01) and by the ethics committees at all participating institutions: CEIC Area 7 Hospital Clínico San Carlos, CEIC Hospital de la Santa Cruz y San Pablo, CEIC del Hospital Universitari Vall d’Hebron, CEIC del Instituto Nacional de Enfermedades Neoplásicas “Dr. Eduardo Cáceres Grazini”, CEIC GAE La Princesa Area 2, CEIC Area Valladolid Este and CEIC Area 1- Hospital General Universitario Gregorio Marañón at Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) as reference Ethical Committee.The study was finally registered at ExternalRef removed (NCT01560663). All patients signed a written informed consent.
: No individual person’s data is provided neither was present in any step of the performed analyses.
: C.M.P is an equity stock holder, consultant, and Board of Director Member, of BioClassifier LLC. C.M.P is also listed an inventor on patent applications on the Breast PAM50 assay. J.S.P is an inventor on patent applications on the Breast PAM50 assay.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.